BRAFV600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts

Cell Reports

Volumn 16, Issue 1, 2016, Pages 263-277

  Kemper, Kristel ^a   Krijgsman, Oscar ^a   Kong, Xiangjun ^a   Cornelissen Steijger, Paulien ^a   Shahrabi, Aida ^a   Weeber, Fleur ^a   van der Velden, Daphne L ^a   Bleijerveld, Onno B ^a   Kuilman, Thomas ^a   Kluin, Roel J C ^a   Sun, Chong ^a   Voest, Emile E ^a   Ju, Young Seok ^b   Schumacher, Ton N M ^a   Altelaar, A F Maarten ^a,c   McDermott, Ultan ^b   Adams, David J ^b   Blank, Christian U ^a   Haanen, John B ^a   Peeper, Daniel S ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; INDOLE DERIVATIVE; SULFONAMIDE; TUMOR MARKER; VEMURAFENIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAF GENE; CANCER INHIBITION; CANCER RESISTANCE; COHORT ANALYSIS; CONTROLLED STUDY; DIMERIZATION; GENE DUPLICATION; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; METASTATIC MELANOMA; MOUSE; NONHUMAN; ONCOGENE N RAS; PROCESS OPTIMIZATION; ANIMAL; CHEMISTRY; CHROMOSOME ABERRATION; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; MAPK SIGNALING; MELANOMA; METABOLISM; METASTASIS; MUTATION; PATHOLOGY; PROTEIN DOMAIN; PROTEIN MULTIMERIZATION; REPRODUCIBILITY; TUMOR CELL LINE;

ANIMALS; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; DRUG RESISTANCE, NEOPLASM; GENE DUPLICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; MAP KINASE SIGNALING SYSTEM; MELANOMA; MICE; MUTATION; NEOPLASM METASTASIS; PROTEIN DOMAINS; PROTEIN MULTIMERIZATION; PROTO-ONCOGENE PROTEINS B-RAF; REPRODUCIBILITY OF RESULTS; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85008196691     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.05.064     Document Type: Article

References (53)

1. Basile, K.J., Abel, E.V., Aplin, A.E., Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells. Oncogene 31 (2012), 2471–2479.
2. Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 1 (2011), 508–523.
3. Burchill, S.A., What do, can and should we learn from models to evaluate potential anticancer agents?. Future Oncol. 2 (2006), 201–211.
4. Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 161 (2015), 1681–1696.
5. Chapman, P.B., Hauschild, A., Robert, C., Haanen, J.B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al., BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364 (2011), 2507–2516.
6. Clement, V., Sanchez, P., de Tribolet, N., Radovanovic, I., Ruiz i Altaba, A., HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr. Biol. 17 (2007), 165–172.
7. Daniel, V.C., Marchionni, L., Hierman, J.S., Rhodes, J.T., Devereux, W.L., Rudin, C.M., Yung, R., Parmigiani, G., Dorsch, M., Peacock, C.D., Watkins, D.N., A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 69 (2009), 3364–3373.
8. Das Thakur, M., Salangsang, F., Landman, A.S., Sellers, W.R., Pryer, N.K., Levesque, M.P., Dummer, R., McMahon, M., Stuart, D.D., Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494 (2013), 251–255.
9. Davies, H., Bignell, G.R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M.J., Bottomley, W., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002), 949–954.
10. De Witt Hamer, P.C., Van Tilborg, A.A.G., Eijk, P.P., Sminia, P., Troost, D., Van Noorden, C.J.F., Ylstra, B., Leenstra, S., The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids. Oncogene 27 (2008), 2091–2096.
11. DeRose, Y.S., Wang, G., Lin, Y.-C., Bernard, P.S., Buys, S.S., Ebbert, M.T.W., Factor, R., Matsen, C., Milash, B.A., Nelson, E., et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat. Med. 17 (2011), 1514–1520.
12. Einarsdottir, B.O., Bagge, R.O., Bhadury, J., Jespersen, H., Mattsson, J., Nilsson, L.M., Truvé, K., López, M.D., Naredi, P., Nilsson, O., et al. Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions. Oncotarget 5 (2014), 9609–9618.
13. Eleveld, T.F., Oldridge, D.A., Bernard, V., Koster, J., Daage, L.C., Diskin, S.J., Schild, L., Bentahar, N.B., Bellini, A., Chicard, M., et al. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat. Genet. 47 (2015), 864–871.
14. Flaherty, K.T., Puzanov, I., Kim, K.B., Ribas, A., McArthur, G.A., Sosman, J.A., O'Dwyer, P.J., Lee, R.J., Grippo, J.F., Nolop, K., Chapman, P.B., Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363 (2010), 809–819.
15. Gallant, J.-N., Sheehan, J.H., Shaver, T.M., Bailey, M., Lipson, D., Chandramohan, R., Red Brewer, M., York, S.J., Kris, M.G., Pietenpol, J.A., et al. EGFR kinase domain duplication (EGFR-KDD) is a novel oncogenic driver in lung cancer that is clinically responsive to afatinib. Cancer Discov. 5 (2015), 1155–1163.
16. Gao, H., Korn, J.M., Ferretti, S., Monahan, J.E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat. Med. 21 (2015), 1318–1325.
17. Garraway, L.A., Widlund, H.R., Rubin, M.A., Getz, G., Berger, A.J., Ramaswamy, S., Beroukhim, R., Milner, D.A., Granter, S.R., Du, J., et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436 (2005), 117–122.
18. Girotti, M.R., Gremel, G., Lee, R., Galvani, E., Rothwell, D., Viros, A., Mandal, A.K., Lim, K.H.J., Saturno, G., Furney, S.J., et al. Application of sequencing, liquid biopsies, and patient-derived xenografts for personalized medicine in melanoma. Cancer Discov. 6 (2016), 286–299.
19. Hoek, K.S., Schlegel, N.C., Brafford, P., Sucker, A., Ugurel, S., Kumar, R., Weber, B.L., Nathanson, K.L., Phillips, D.J., Herlyn, M., et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res. 19 (2006), 290–302.
20. Hugo, W., Shi, H., Sun, L., Piva, M., Song, C., Kong, X., Moriceau, G., Hong, A., Dahlman, K.B., Johnson, D.B., et al. Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. Cell 162 (2015), 1271–1285.
21. Kemper, K., Krijgsman, O., Cornelissen-Steijger, P., Shahrabi, A., Weeber, F., Song, J.-Y., Kuilman, T., Vis, D.J., Wessels, L.F., Voest, E.E., et al. Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts. EMBO Mol. Med. 7 (2015), 1104–1118.
22. Konieczkowski, D.J., Johannessen, C.M., Abudayyeh, O., Kim, J.W., Cooper, Z.A., Piris, A., Frederick, D.T., Barzily-Rokni, M., Straussman, R., Haq, R., et al. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov. 4 (2014), 816–827.
23. Kuilman, T., Velds, A., Kemper, K., Ranzani, M., Bombardelli, L., Hoogstraat, M., Nevedomskaya, E., Xu, G., de Ruiter, J., Lolkema, M.P., et al. CopywriteR: DNA copy number detection from off-target sequence data. Genome Biol., 16, 2015, 49.
24. Larkin, J., Ascierto, P.A., Dréno, B., Atkinson, V., Liszkay, G., Maio, M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med. 371 (2014), 1867–1876.
25. Marranci, A., Tuccoli, A., Vitiello, M., Mercoledi, E., Sarti, S., Lubrano, S., Evangelista, M., Fogli, A., Valdes, C., Russo, F., et al. Identification of BRAF 3’UTR Isoforms in Melanoma. J. Invest. Dermatol. 135 (2015), 1694–1697.
26. Monsma, D.J., Monks, N.R., Cherba, D.M., Dylewski, D., Eugster, E., Jahn, H., Srikanth, S., Scott, S.B., Richardson, P.J., Everts, R.E., et al. Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue. J. Transl. Med., 10, 2012, 125.
27. Monsma, D.J., Cherba, D.M., Eugster, E.E., Dylewski, D.L., Davidson, P.T., Peterson, C.A., Borgman, A.S., Winn, M.E., Dykema, K.J., Webb, C.P., et al. Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms. Am. J. Cancer Res. 5 (2015), 1507–1518.
28. Müller, J., Krijgsman, O., Tsoi, J., Robert, L., Hugo, W., Song, C., Kong, X., Possik, P.A., Cornelissen-Steijger, P.D.M., Foppen, M.H.G., et al. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat. Commun., 5, 2014, 5712.
29. Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R.C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468 (2010), 973–977.
30. Nikolaev, S.I., Rimoldi, D., Iseli, C., Valsesia, A., Robyr, D., Gehrig, C., Harshman, K., Guipponi, M., Bukach, O., Zoete, V., et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat. Genet. 44 (2011), 133–139.
31. Ozer, B.H., Wiepz, G.J., Bertics, P.J., Activity and cellular localization of an oncogenic glioblastoma multiforme-associated EGF receptor mutant possessing a duplicated kinase domain. Oncogene 29 (2010), 855–864.
32. Paraiso, K.H.T., Xiang, Y., Rebecca, V.W., Abel, E.V., Chen, Y.A., Munko, A.C., Wood, E., Fedorenko, I.V., Sondak, V.K., Anderson, A.R.A., et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 71 (2011), 2750–2760.
33. Parikh, C., Janakiraman, V., Wu, W.-I., Foo, C.K., Kljavin, N.M., Chaudhuri, S., Stawiski, E., Lee, B., Lin, J., Li, H., et al. Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers. Proc. Natl. Acad. Sci. USA 109 (2012), 19368–19373.
34. Peng, S.-B., Henry, J.R., Kaufman, M.D., Lu, W.-P., Smith, B.D., Vogeti, S., Rutkoski, T.J., Wise, S., Chun, L., Zhang, Y., et al. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. Cancer Cell 28 (2015), 384–398.
35. Possik, P.A., Müller, J., Gerlach, C., Kenski, J.C.N., Huang, X., Shahrabi, A., Krijgsman, O., Song, J.-Y., Smit, M.A., Gerritsen, B., et al. Parallel in vivo and in vitro melanoma RNAi dropout screens reveal synthetic lethality between hypoxia and DNA damage response inhibition. Cell Rep. 9 (2014), 1375–1386.
36. Poulikakos, P.I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M.T., et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480 (2011), 387–390.
37. Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 372 (2015), 30–39.
38. Rubio-Viqueira, B., Jimeno, A., Cusatis, G., Zhang, X., Iacobuzio-Donahue, C., Karikari, C., Shi, C., Danenberg, K., Danenberg, P.V., Kuramochi, H., et al. An in vivo platform for translational drug development in pancreatic cancer. Clin. Cancer Res. 12 (2006), 4652–4661.
39. Shi, H., Moriceau, G., Kong, X., Lee, M.-K., Lee, H., Koya, R.C., Ng, C., Chodon, T., Scolyer, R.A., Dahlman, K.B., et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat. Commun., 3, 2012, 724.
40. Shi, H., Hong, A., Kong, X., Koya, R.C., Song, C., Moriceau, G., Hugo, W., Yu, C.C., Ng, C., Chodon, T., et al. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov. 4 (2014), 69–79.
41. Shi, H., Hugo, W., Kong, X., Hong, A., Koya, R.C., Moriceau, G., Chodon, T., Guo, R., Johnson, D.B., Dahlman, K.B., et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 4 (2014), 80–93.
42. Solit, D.B., Rosen, N., Towards a unified model of RAF inhibitor resistance. Cancer Discov. 4 (2014), 27–30.
43. Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z.R., Du, J., Davis, A., Mongare, M.M., Gould, J., Frederick, D.T., et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487 (2012), 500–504.
44. Sun, C., Wang, L., Huang, S., Heynen, G.J.J.E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S.M., et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 508 (2014), 118–122.
45. Van Allen, E.M., Wagle, N., Sucker, A., Treacy, D.J., Johannessen, C.M., Goetz, E.M., Place, C.S., Taylor-Weiner, A., Whittaker, S., Kryukov, G.V., et al., Dermatologic Cooperative Oncology Group of Germany (DeCOG). The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 4 (2014), 94–109.
46. Verfaillie, A., Imrichova, H., Atak, Z.K., Dewaele, M., Rambow, F., Hulselmans, G., Christiaens, V., Svetlichnyy, D., Luciani, F., Van den Mooter, L., et al. Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state. Nat. Commun., 6, 2015, 6683.
47. Vergani, E., Vallacchi, V., Frigerio, S., Deho, P., Mondellini, P., Perego, P., Cassinelli, G., Lanzi, C., Testi, M.A., Rivoltini, L., et al. Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032. Neoplasia 13 (2011), 1132–1142.
48. Voskoglou-Nomikos, T., Pater, J.L., Seymour, L., Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin. Cancer Res. 9 (2003), 4227–4239.
49. Vredeveld, L.C.W., Possik, P.A., Smit, M.A., Meissl, K., Michaloglou, C., Horlings, H.M., Ajouaou, A., Kortman, P.C., Dankort, D., McMahon, M., et al. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev. 26 (2012), 1055–1069.
50. Wagenaar, T.R., Ma, L., Roscoe, B., Park, S.M., Bolon, D.N., Green, M.R., Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain. Pigment Cell Melanoma Res. 27 (2014), 124–133.
51. Wagle, N., Emery, C., Berger, M.F., Davis, M.J., Sawyer, A., Pochanard, P., Kehoe, S.M., Johannessen, C.M., Macconaill, L.E., Hahn, W.C., et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 29 (2011), 3085–3096.
52. Wagle, N., Van Allen, E.M., Treacy, D.J., Frederick, D.T., Cooper, Z.A., Taylor-Weiner, A., Rosenberg, M., Goetz, E.M., Sullivan, R.J., Farlow, D.N., et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 4 (2014), 61–68.
53. Zhang, L., Zhou, Y., Cheng, C., Cui, H., Cheng, L., Kong, P., Wang, J., Li, Y., Chen, W., Song, B., et al. Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma. Am. J. Hum. Genet. 96 (2015), 597–611.